{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:09:10Z","timestamp":1782248950848,"version":"3.54.5"},"reference-count":32,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":1888,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J\n                        Psychiatry"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Atypical antipsychotics are widely used in bipolar mania. However, the\n                           efficacy of atypical antipsychotics in bipolar depression has not been\n                           comprehensively explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To evaluate olanzapine monotherapy in patients with bipolar\n                           depression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Patients with bipolar depression received olanzapine (5\u201320mg\/day,\n                              <jats:italic>n<\/jats:italic> = 343) or placebo (<jats:italic>n<\/jats:italic> = l71) for 6\n                           weeks. The primary outcome was change from baseline to end-point in\n                           Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score. Secondary\n                           outcomes included: Clinical Global impression - Bipolar Version (CGI-BP)\n                           scale, 17-item Hamilton Rating Scale for Depression (HRSD-17) and Young\n                           Mania Rating Scale (YMRS) scores, and the rate of response (\u226550%\n                           reduction in MADRS at end-point), recovery (MADRS \u226412 for \u22654 weeks plus\n                           treatment completion) and remission (MADRS \u22648). The trial was registered\n                           with ClinicalTrials.gov (NCT00510146).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Olanzapine demonstrated: significantly greater\n                           (<jats:italic>P<\/jats:italic>&lt;0.04) improvements on MADRS (least-squares mean\n                           change -13.82 <jats:italic>v.<\/jats:italic> -11.67), HRSD-17 and YMRS total scores\n                           and all CGI-BP subscale scores <jats:italic>v.<\/jats:italic> placebo; significantly\n                              (<jats:italic>P<\/jats:italic>\u22640.05) more response and remission, but not\n                           recovery; significantly (<jats:italic>P<\/jats:italic>&lt;0.01) greater mean\n                           increases in weight, fasting cholesterol and triglycerides; and\n                           significantly more (<jats:italic>P<\/jats:italic>&lt;0.001) patients gained \u22657% body\n                           weight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Olanzapine monotherapy appears to be efficacious in bipolar depression.\n                           Additional long-term studies are warranted to confirm these results.\n                           Safety findings were consistent with the known safety profile of\n                           olanzapine.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.bp.112.108357","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T01:17:31Z","timestamp":1345771051000},"page":"376-382","source":"Crossref","is-referenced-by-count":101,"title":["Randomised, double-blind, placebo-controlled study of olanzapine\n                        in patients with bipolar I depression"],"prefix":"10.1192","volume":"201","author":[{"given":"Mauricio","family":"Tohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenobu","family":"Kanba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyooseob","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Ru","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Carlos","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000272851_ref21","first-page":"22","article-title":"The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"S0007125000272851_ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.14.1840"},{"key":"S0007125000272851_ref23","doi-asserted-by":"crossref","unstructured":"Komossa K , Depping AM , Gaudchau A , Kissling W , Leucht S . Secondgeneration antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010; CD008121.","DOI":"10.1002\/14651858.CD008121.pub2"},{"key":"S0007125000272851_ref26","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn110"},{"key":"S0007125000272851_ref8","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05934"},{"key":"S0007125000272851_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.10.026"},{"key":"S0007125000272851_ref5","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000248603.76231.b7"},{"key":"S0007125000272851_ref1","first-page":"e06","article-title":"Long-term treatment of bipolar disorder in adults","volume":"72","author":"Mclntyre","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"S0007125000272851_ref2","article-title":"Long-term worsening of bipolar disorder related with frequency of antidepressant exposure","volume":"23","author":"Strejilevich","year":"2011","journal-title":"Ann Clin Psychiatry"},{"key":"S0007125000272851_ref22","volume-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report","year":"2002"},{"key":"S0007125000272851_ref3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07121931"},{"key":"S0007125000272851_ref4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1351"},{"key":"S0007125000272851_ref29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04984gre"},{"key":"S0007125000272851_ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1096"},{"key":"S0007125000272851_ref7","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e3181618eb4"},{"key":"S0007125000272851_ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.11.1079"},{"key":"S0007125000272851_ref10","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145708009735"},{"key":"S0007125000272851_ref11","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0514"},{"key":"S0007125000272851_ref20","volume-title":"Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage","author":"Inada","year":"1996"},{"key":"S0007125000272851_ref13","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)","year":"2000"},{"key":"S0007125000272851_ref14","article-title":"Development of a rating scale for primary depressive illness","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br J Clin Psychol"},{"key":"S0007125000272851_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(97)00123-6"},{"key":"S0007125000272851_ref15","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"S0007125000272851_ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1147-6"},{"key":"S0007125000272851_ref25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-58"},{"key":"S0007125000272851_ref31","doi-asserted-by":"publisher","DOI":"10.1176\/ps.62.9.pss6209_1032"},{"key":"S0007125000272851_ref32","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04772gre"},{"key":"S0007125000272851_ref12","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"S0007125000272851_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2008.10.025"},{"key":"S0007125000272851_ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00726.x"},{"key":"S0007125000272851_ref17","doi-asserted-by":"publisher","DOI":"10.3109\/13651501.2011.632680"},{"key":"S0007125000272851_ref30","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09r05535gre"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000272851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T22:06:30Z","timestamp":1556143590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000272851\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0007125000272851"],"URL":"https:\/\/doi.org\/10.1192\/bjp.bp.112.108357","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}